Iterum Therapeutics PLC (ITRM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iterum Therapeutics PLC (ITRM) has a cash flow conversion efficiency ratio of 1.063x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.85 Million) by net assets ($-7.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Iterum Therapeutics PLC worth for the company's overall valuation and market capitalisation.
Iterum Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Iterum Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Iterum Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iterum Therapeutics PLC ranked by their cash flow conversion efficiency. Explore Iterum Therapeutics PLC cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Magnetic North Acquisition Corp
V:MNC
|
0.115x |
|
Capricorn Energy PLC
LSE:CNE
|
0.335x |
|
Bluelinea SA
PA:ALBLU
|
-0.615x |
|
Fidelity Japanese Values PLC ORD
LSE:FJV
|
-0.002x |
|
Albion Enterprise VCT PLC
LSE:AAEV
|
-0.005x |
|
Olympio Metals Ltd
AU:OLY
|
-2.352x |
|
EQTEC plc
LSE:EQT
|
-0.273x |
|
Australian Silica Quartz Group Ltd
AU:ASQ
|
-0.107x |
Annual Cash Flow Conversion Efficiency for Iterum Therapeutics PLC (2016–2024)
The table below shows the annual cash flow conversion efficiency of Iterum Therapeutics PLC from 2016 to 2024. View Iterum Therapeutics PLC stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.08 Million | $-26.77 Million | 6.560x | +6.79% |
| 2023-12-31 | $-6.40 Million | $-39.33 Million | 6.142x | +1030.99% |
| 2022-12-31 | $28.00 Million | $-18.47 Million | -0.660x | -109.21% |
| 2021-12-31 | $50.23 Million | $-15.84 Million | -0.315x | -129.24% |
| 2020-12-31 | $-50.56 Million | $-54.53 Million | 1.079x | -65.46% |
| 2019-12-31 | $-26.24 Million | $-81.92 Million | 3.122x | +394.67% |
| 2018-12-31 | $71.62 Million | $-75.89 Million | -1.060x | -36.74% |
| 2017-12-31 | $39.49 Million | $-30.60 Million | -0.775x | -55.47% |
| 2016-12-31 | $22.67 Million | $-11.30 Million | -0.498x | -- |
About Iterum Therapeutics PLC
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with lim… Read more